Investigators at CHOP and UPenn found that lower cell counts could still be associated with poor outcomes if the cells were ...

The NICE committee concluded that it needed additional data on various survival endpoints and further cost-effectiveness analyses.

The trial will include patients with MTAP-deleted pancreatic or MTAP-deleted RAS-mutant non-small cell lung cancer.

The firm will use the $19 million it raised in Series A financing to finish developing its platform that can help decentralize CAR T-cell therapy.

The collaboration initially will focus on developing an mRNA therapy for a type of lung fibrosis and an ASO for Lamb-Shaffer syndrome.

An ongoing Phase III trial aims to further evaluate the drug's clinical efficacy in reducing seizures and affecting behavior and cognition.

The group has already helped pass bills in Arkansas and Oklahoma, and is supporting bills introduced in Florida, Mississippi, and Tennessee.

Two former FDA veterans are worried that a "firewall" between politics and scientific regulatory decisions has been breached, risking the agency's reputation and leadership.

The firm believes that clinical data generated to date from two patients may be sufficient to support accelerated approval of PM359.

While the US Food and Drug Administration touts new regulatory flexibility for rare disease drugs, recent rejections of ...

Researchers will test the cell therapy in a dozen patients with CD19-expressing blood cancers, including diffuse large B-cell lymphoma and B-cell acute lymphoblastic leukemia.

NEW YORK – T-Knife Therapeutics plans to begin a clinical trial this year of its PRAME-targeting armored T cell receptor (TCR) therapy, after the company confirmed on Tuesday that the European ...